Drug Approval | January 13, 2022
South Korea approves Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
The first pilot study from India analyzing Covaxin-Covishield mixed doses
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The company will market it under the brand name Molflu
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Subscribe To Our Newsletter & Stay Updated
